Loading...
KSHV-specific antivirals targeting the protein-DNA interaction of the latency-associated nuclear antigen.
Berwanger, Aylin Empting, Martin
Berwanger, Aylin
Empting, Martin
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-05-26
Submitted date
Files
Loading...
accepted manuscript
Adobe PDF, 1.26 MB
Other Titles
Abstract
The Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic human herpesviruses that is responsible for cancer, especially in immunosuppressed people, such as patients with AIDS. So far, there are no KSHV-specifc antiviral agents available. In this review, we provide an overview on one particular target-centered approach toward novel anti-KSHV drugs focusing on interfering with the molecular functions of the latency-associated nuclear antigen (LANA). This review focuses on attempts to interfere with the LANA-DNA interaction mediated by the C-terminal domain. We describe the drug discovery approaches chosen for this endeavor as well as molecular structures that were identified in this innovative concept toward novel and KSHV-specific antiherpesviral agents.
Citation
Future Med Chem. 2021 Jul;13(13):1141-1151. doi: 10.4155/fmc-2021-0059. Epub 2021 May 26.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Review
Language
en
Description
Series/Report no.
ISSN
EISSN
1756-8927
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International